Abstract 1698
Background
Although gemcitabine plus nab–paclitaxel (GnP) is a standard treatment for advanced pancreatic cancer as the result of phase III trial ((MPACT), its therapeutic benefit for elderly patients is unclear. This study aimed to assess the effectiveness and safety of GnP for these patients.
Methods
We retrospectively enrolled patients aged > =75 years in whom GnP was initiated as first–line treatment for advanced pancreatic cancer between December 2014 and December 2016. Overall survival and progression–free survival according to disease status were calculated using Kaplan–Meier method. Objective response was estimated according to RECISTv1.1. Adverse events were evaluated according to based on the Common Terminology Criteria of Adverse Events version4.0. The incidence of adverse events and early discontinuation (i.e., treatment discontinuation due to adverse events within 2 months from initiation) was compared via Fishers’ exact test for univariate analysis and via logistic regression model with step wise method for multivariate analysis.
Results
The cohort comprised 116 selected patients with a median age of 77 years (range: 75–84 years). Within a median follow-up of 13 months, the median overall survival and progression-free survival of locally advanced cancer patients were 21.8 and 12.1 months, respectively. In patients with metastasis, these were 13.3 and 5.9 months. The response rate was 31% and the disease control rate was 81%. Within the first 2 months of treatment, grade 4 hematological and grade 3–4 non-hematological toxicities were observed in 10 and 23 patients, respectively. Early treatment discontinuation of GnP occurred in 12 patients, and the associated risk factors were age > =80 years [odds ratio (OR), 9.43; 95% confidence interval (CI), 2.25–39.60] and serum albumin <35 g/L (OR, 5.12; 95% CI, 1.11–23.61).
Conclusions
GnP in selected patients aged > =75 years showed acceptable toxicities and comparable effectiveness to that in the previous studies of the non-elderly population, but patients aged > =80 years and with serum albumin <35 d/L should be carefully assessed for treatment eligibility.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Satoshi Kobayashi.
Funding
Has not received any funding.
Disclosure
M. Ozaka: Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self): Novartis Pharma; Honoraria (self): Bayer Yakuhin; Honoraria (self): Yakult Honsha; Honoraria (self): Eisai; Honoraria (self): EA Pharma. S. Kobayashi: Honoraria (self), Research grant / Funding (institution): Taiho pharmaceutical; Honoraria (self): Boston Scientific; Honoraria (self), Speaker Bureau / Expert testimony: Kyowa Hakko Kirin; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Speaker Bureau / Expert testimony: Bayer Yakuhin; Honoraria (self): Teijin Pharma; Honoraria (self), Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Yakult Honsha; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Takara Bio; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): MSD Oncology; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Takeda. M. Ikeda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer Yakuhin; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): Yakult; Honoraria (self): Otsuka Pharmaceutical; Honoraria (self): Nobel Pharma; Honoraria (self), Advisory / Consultancy: Daiichi-Sankyo; Honoraria (self): Sumitomo Dainippon Pharma; Honoraria (self): Teijin Pharma; Honoraria (self): EA Pharma; Honoraria (self): Kaken Pharmaceutical; Advisory / Consultancy: Shire; Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (institution): ASLAN Pharmaceutical; Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharmaceutical; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Baxalta Japan Limited; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Nano Carrier; Research grant / Funding (institution): Takara-Bio. M. Ueno: Honoraria (self), Research grant / Funding (institution): Yakult Honsha; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): ASLAN; Research grant / Funding (institution): Ono pharmaceutical; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Eisai; Honoraria (self): Novel pharma; Honoraria (self): Novartis; Honoraria (self): Teijin Pharma; Research grant / Funding (institution): Takara Bio.
Resources from the same session
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract
2104 - Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation
Presenter: Jwa Hoon Kim
Session: Poster Display session 2
Resources:
Abstract
2143 - Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)
Presenter: Shin Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3136 - Trifluridine/tipiracil in metastatic colorectal cancer: an updated multicentre real-world analysis on efficacy, safety and predictive factors.
Presenter: Chara Stavraka
Session: Poster Display session 2
Resources:
Abstract
4234 - Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
Presenter: Eleonora Lai
Session: Poster Display session 2
Resources:
Abstract
4287 - Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
Presenter: Ian Chau
Session: Poster Display session 2
Resources:
Abstract
1820 - A Phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Johanna Bendell
Session: Poster Display session 2
Resources:
Abstract
5644 - Development and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer
Presenter: Zhiwen Luo
Session: Poster Display session 2
Resources:
Abstract
5697 - Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial
Presenter: Giovanni Fuca
Session: Poster Display session 2
Resources:
Abstract
4704 - Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker
Presenter: Joleen Hubbard
Session: Poster Display session 2
Resources:
Abstract